CY1112442T1 - Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης - Google Patents

Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης

Info

Publication number
CY1112442T1
CY1112442T1 CY20121100228T CY121100228T CY1112442T1 CY 1112442 T1 CY1112442 T1 CY 1112442T1 CY 20121100228 T CY20121100228 T CY 20121100228T CY 121100228 T CY121100228 T CY 121100228T CY 1112442 T1 CY1112442 T1 CY 1112442T1
Authority
CY
Cyprus
Prior art keywords
pyridinone derivatives
atherosclerosis therapy
atherosclerosis
therapy
pyridinone
Prior art date
Application number
CY20121100228T
Other languages
English (en)
Inventor
Deirdre Mary B Hickey
Robert John Ife
Colin Andrew Leach
John Liddle
Ivan Leo Pinto
Stephen Allen Smith
Steven James Stanway
Original Assignee
Smithkline Beecham Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Limited filed Critical Smithkline Beecham Limited
Publication of CY1112442T1 publication Critical patent/CY1112442T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Οι ενώσεις του τύπου (Ι): είναι αναστολείς του ενζύμου Lp-PLA2 και χρησιμοποιούνται στην θεραπεία, ιδιαιτέρως για θεραπεία αθηροσκλήρωσης.
CY20121100228T 2000-10-10 2012-03-07 Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης CY1112442T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0024808.8A GB0024808D0 (en) 2000-10-10 2000-10-10 Novel compounds
EP01978400A EP1326841B1 (en) 2000-10-10 2001-10-05 Pyridinone derivatives for treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
CY1112442T1 true CY1112442T1 (el) 2015-12-09

Family

ID=9901006

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100228T CY1112442T1 (el) 2000-10-10 2012-03-07 Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
CY20131100118T CY1113648T1 (el) 2000-10-10 2013-02-08 Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100118T CY1113648T1 (el) 2000-10-10 2013-02-08 Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης

Country Status (29)

Country Link
US (2) US20040063753A1 (el)
EP (2) EP1326841B1 (el)
JP (1) JP4212354B2 (el)
KR (1) KR100824134B1 (el)
CN (2) CN1951917B (el)
AR (1) AR035349A1 (el)
AT (1) ATE538096T1 (el)
AU (2) AU2002210524B2 (el)
BR (1) BRPI0114576B1 (el)
CA (1) CA2425268C (el)
CY (2) CY1112442T1 (el)
CZ (1) CZ304558B6 (el)
DK (2) DK1326841T3 (el)
ES (2) ES2378059T3 (el)
GB (1) GB0024808D0 (el)
GC (1) GC0000307A (el)
HK (2) HK1144941A1 (el)
HU (1) HU230767B1 (el)
IL (2) IL155278A0 (el)
MX (1) MXPA03003176A (el)
MY (1) MY135766A (el)
NO (1) NO325107B1 (el)
NZ (1) NZ525225A (el)
PL (1) PL207560B1 (el)
PT (2) PT2258688E (el)
SI (2) SI2258688T1 (el)
TW (1) TWI293293B (el)
WO (1) WO2002030904A1 (el)
ZA (1) ZA200302785B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3546601A (en) * 2000-02-16 2001-08-27 Smithkline Beecham Plc Pyrimidine-4-one derivatives as LDL-PLA<sub>2</sub> inhibitors
GB0119793D0 (en) * 2001-08-14 2001-10-03 Smithkline Beecham Plc Novel compounds
GB0127140D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0127139D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Novel compounds
GB0208279D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
GB0208280D0 (en) * 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
JP4812751B2 (ja) 2004-04-16 2011-11-09 グラクソ グループ リミテッド Ｌｐ−ＰＬＡ２活性およびＬｐ−ＰＬＡ２活性阻害を検出する方法
US7705005B2 (en) * 2006-10-13 2010-04-27 Glaxo Group Limited Bicyclic heteroaromatic compounds
US20080090852A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
US20080090851A1 (en) * 2006-10-13 2008-04-17 Colin Andrew Leach Bicyclic Heteroaromatic Compounds
MX2009012197A (es) 2007-05-11 2010-01-15 Univ Pennsylvania Metodos para tratamiento de ulceras en la piel.
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US8575348B2 (en) 2009-07-28 2013-11-05 Auspex Pharmaceuticals, Inc Quinolone inhibitors of lipoprotein-associated phospholipase A2
US9512104B2 (en) * 2009-07-28 2016-12-06 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase A2
US20120220624A1 (en) * 2009-10-19 2012-08-30 Tony Siu Pyrazolo [3,4-b] pyridin-4-one kinase inhibitors
US9011821B2 (en) 2010-06-18 2015-04-21 Whitehead Institute For Biomedical Research PLA2G16 as a target for antiviral compounds
JP2013544854A (ja) * 2010-12-06 2013-12-19 グラクソ グループ リミテッド 化合物
MX2013006342A (es) * 2010-12-06 2013-08-26 Glaxo Group Ltd Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2).
US20130267544A1 (en) 2010-12-17 2013-10-10 Peter Adamson Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases
WO2013000108A1 (zh) * 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
WO2013013503A1 (en) 2011-07-27 2013-01-31 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1h)-one compounds use as lp-pla2 inhibitors
EP2736908A1 (en) 2011-07-27 2014-06-04 Glaxo Group Limited Bicyclic pyrimidone compounds
EP2751094B1 (en) 2011-09-01 2018-06-20 Glaxo Group Limited Novel crystal form
SG11201505520WA (en) 2013-01-25 2015-08-28 Glaxosmithkline Ip Dev Ltd 2,3-DIHYDROIMIDAZOL[1,2-C]PYRIMIDIN-5(1H)-ONE BASED LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 (LP-PLA<sb>2</sb>) INHIBITORS
EP2948456A4 (en) 2013-01-25 2016-09-14 Glaxosmithkline Ip Dev Ltd BICYCLIC PYRIMIDONE COMPOUNDS AS LP-PLA2 INHIBITORS
CN105008365B (zh) 2013-01-25 2017-03-15 葛兰素史密斯克莱知识产权发展有限公司 化合物
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
US20140283157A1 (en) 2013-03-15 2014-09-18 Diadexus, Inc. Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CN104840963B (zh) * 2015-05-26 2018-02-16 河北东康生物科技有限公司 含脂蛋白相关性磷脂酶a2抑制剂的药物组合物及应用
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
CN112574221B (zh) * 2019-09-30 2022-03-04 上海纽思克生物科技有限公司 四环嘧啶酮类化合物、其制备方法、其组合物和用途
AU2020379796C1 (en) 2019-11-09 2024-05-02 Shanghai SIMR Biotechnology Co., Ltd Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof
CN112510260B (zh) * 2020-11-27 2022-11-04 珠海市赛纬电子材料股份有限公司 电解液添加剂、非水电解液和锂离子电池
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5769527A (en) 1986-07-17 1998-06-23 Vari-Lite, Inc. Computer controlled lighting system with distributed control resources
US5585246A (en) 1993-02-17 1996-12-17 Biometric Imaging, Inc. Method for preparing a sample in a scan capillary for immunofluorescent interrogation
DE69423436T2 (de) 1993-06-25 2000-09-07 Smithkline Beecham P.L.C., Brentford An lipoprotein gebundene phospholipase a2, inhibitoren davon und deren verwendung für diagnose und therapie
ATE201905T1 (de) 1993-10-06 2001-06-15 Icos Corp Acethylhydrolase des plättchen aktivierenden faktors
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
CA2208530A1 (en) 1994-12-22 1996-06-27 Smithkline Beecham P.L.C. Substituted azetidin-2-ones for treatment of atherosclerosis
CH690264A5 (fr) 1995-06-30 2000-06-30 Symphar Sa Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
KR19990028630A (ko) 1995-07-01 1999-04-15 데이비드 로버츠 아테롬성 동맥경화증을 치료하기 위한 아제티디논 유도체
FR2743912B1 (fr) 1996-01-24 1998-04-10 Matra Communication Circuit de resolution d'equation-cle et decodeur reed-solomon incorporant un tel circuit
US5684794A (en) 1996-01-25 1997-11-04 Hazeltine Corporation Validation of subscriber signals in a cellular radio network
GB9608649D0 (en) 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel compounds
AU735901C (en) * 1996-12-05 2004-02-12 Amgen, Inc. Substituted pyrimidinone and pyridone compounds and methods of use
GB9626615D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626536D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
GB9626616D0 (en) 1996-12-20 1997-02-05 Symphar Sa Novel compounds
AU1157599A (en) 1997-11-06 1999-05-31 Smithkline Beecham Plc Pyrimidinone compounds and pharmaceutical compositions containing them
EP1105377B1 (en) 1998-08-21 2003-10-08 SmithKline Beecham plc Pyrimidinone derivatives for the treatment of atherosclerosis
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
AU766003B2 (en) 1999-05-01 2003-10-09 Smithkline Beecham Plc Pyrimidinone compounds
GB9910378D0 (en) 1999-05-05 1999-06-30 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU2002210524B2 (en) 2004-06-03
KR20030036916A (ko) 2003-05-09
NO20031626L (no) 2003-06-04
EP1326841A1 (en) 2003-07-16
US7235566B2 (en) 2007-06-26
ES2399325T3 (es) 2013-03-27
BRPI0114576B1 (pt) 2017-05-30
KR100824134B1 (ko) 2008-04-21
HUP0302480A3 (en) 2010-03-29
GB0024808D0 (en) 2000-11-22
US20040063753A1 (en) 2004-04-01
US20050014793A1 (en) 2005-01-20
IL155278A (en) 2015-05-31
HK1058036A1 (en) 2004-04-30
HUP0302480A2 (hu) 2003-12-29
ZA200302785B (en) 2004-07-09
EP2258688B1 (en) 2012-11-21
MY135766A (en) 2008-06-30
SI1326841T1 (sl) 2012-04-30
BR0114576A (pt) 2004-07-27
AR035349A1 (es) 2004-05-12
ES2378059T3 (es) 2012-04-04
CN1951917B (zh) 2012-07-18
PT1326841E (pt) 2012-03-08
CY1113648T1 (el) 2016-06-22
PL366334A1 (en) 2005-01-24
NZ525225A (en) 2004-10-29
GC0000307A (en) 2006-11-01
DK2258688T3 (da) 2013-02-04
ATE538096T1 (de) 2012-01-15
CZ20031009A3 (cs) 2003-11-12
CA2425268C (en) 2011-09-13
HU230767B1 (hu) 2018-03-28
JP2004512283A (ja) 2004-04-22
EP1326841B1 (en) 2011-12-21
MXPA03003176A (es) 2003-07-14
CZ304558B6 (cs) 2014-07-09
CN1951917A (zh) 2007-04-25
DK1326841T3 (da) 2012-02-27
NO20031626D0 (no) 2003-04-09
CA2425268A1 (en) 2002-04-18
IL155278A0 (en) 2003-11-23
WO2002030904A1 (en) 2002-04-18
CN1280275C (zh) 2006-10-18
SI2258688T1 (sl) 2013-03-29
TWI293293B (en) 2008-02-11
HK1144941A1 (en) 2011-03-18
CN1479724A (zh) 2004-03-03
JP4212354B2 (ja) 2009-01-21
PL207560B1 (pl) 2011-01-31
PT2258688E (pt) 2013-02-04
EP2258688A1 (en) 2010-12-08
AU1052402A (en) 2002-04-22
NO325107B1 (no) 2008-02-04

Similar Documents

Publication Publication Date Title
CY1112442T1 (el) Παραγωγα πυριδινονης για θεραπεια αθηροσκληρωσης
CY1109484T1 (el) Παραγωγα πυριμιδιν-5-ονης ως αναστολεις της ldl-pla2
TR200103216T2 (tr) Pirimidinon bileşimleri
DK1372650T3 (da) Kombinationer indeholdende et antidiarrémiddel og en epothilon eller et epothilonderivat
CY1108874T1 (el) ΧΡΗΣΗ ΤΩΝ ΑΝΑΣΤΟΛΕΩΝ Ι κΒ- ΚΙΝΑΣΗΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΠΟΝΟΥ
ATE336248T1 (de) Verwendung von thiazolidinderivaten als antihyperglykämische mittel
CY1106139T1 (el) Αρυλπιπepαζινες και η χρηση τους ως μεσων αναστολης μεταλλοπρωτεϊνασης (μμρ)
NO20050427L (no) Carvedilolfosfatsalter og/eller solvater derav, tilsvarende preparater og/eller behandlingsfremgangsmater
NO20005224L (no) BTK inhibitorer og fremgangsmåter for deres identifikasjon og anvendelse
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
CY1121982T1 (el) Συνθεσεις syn3 και μεθοδοι
DE60042401D1 (de) Fab-i inhibitoren
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE69814894D1 (de) Isochinolin derivate als urokinase inhibitoren
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE337320T1 (de) Indolderivate als pde5-inhibitoren
TR200100133T2 (tr) FKBP İnhibitörleri
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
MXPA02011558A (es) Inhibidores de mmp-2/mp-9 novedosos.
NO970341L (no) Imidazopyridin-azolidinoner
ATE322898T1 (de) Inhibitoren von mycobakterien
BR0015402A (pt) Derivados de ácido 15-hidroxieicosatetraenóico de cadeia Èmega modificada e métodos de seu uso para o tratamento de olho seco
AU2576901A (en) Agents and methods for the treatment of proliferative diseases